Novo Nordisk Shares Drop on Drug Trial Failure
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk shares dropped after a drug candidate failed in a clinical trial, according to coverage from Reuters, the Wall Street Journal, and Investor's Business Daily
- The failed candidate was an inflammation-targeting drug tested in heart disease, contributing to a broader slump in weight loss drug stocks
Why it matters: The trial miss is a setback to Novo Nordisk's diversification strategy beyond its blockbuster obesity drug Ozempic, and the broader weight loss drug sector sold off on the news — signaling that investors were treating this pipeline candidate as material to the category's growth narrative.
